Marshall Wace North America’s Jazz Pharmaceuticals JAZZ Stock Holding History

Marshall Wace North America’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,228	Closed	-$3.49M	–	1609
2021 Q1	$3.49M	Buy	21,228 +4,455	+27%	+$733K	0.01%	657
2020 Q4	$2.77M	Buy	16,773 +481	+3%	+$71.6K	0.01%	680
2020 Q3	$2.32M	Sell	16,292 -76,894	-83%	-$9.53M	0.01%	546
2020 Q2	$10.3M	Buy	+93,186	New	+$10.3M	0.07%	265
2020 Q1	–	Sell	-4,406	Closed	-$657K	–	1414
2019 Q4	$657K	Buy	+4,406	New	+$600K	﹤0.01%	789
2019 Q2	–	Sell	-37,681	Closed	-$5.39M	–	1357
2019 Q1	$5.39M	Sell	37,681 -9,026	-19%	-$1.18M	0.04%	316
2018 Q4	$5.79M	Buy	+46,707	New	+$6.93M	0.06%	229
2018 Q2	–	Sell	-6,664	Closed	-$1.01M	–	1532
2018 Q1	$1.01M	Buy	+6,664	New	+$978K	0.01%	998
2013 Q4	$2.22M	Buy	+17,575	New	+$1.82M	0.05%	278
2013 Q3	–	Sell	-24,450	Closed	-$1.68M	–	655
2013 Q2	$1.68M	Buy	+24,450	New	+$1.49M	0.13%	189

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace North America's JAZZ Position: Q2 2021 in Review

Marshall Wace North America sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2021, closing a stake of 21,228 shares — an estimated $3.49M sold.

Marshall Wace North America first reported a position in JAZZ in Q2 2013 and held it in 10 quarters. The position peaked at $10.3M in Q2 2020. 505 funds tracked by Wall St. Rank hold JAZZ as of Q2 2021.

Marshall Wace North America reported no remaining Jazz Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 21,228 Jazz Pharmaceuticals shares in Q2 2021, an estimated $3.49M.
Marshall Wace North America first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Marshall Wace North America's Jazz Pharmaceuticals position peaked at $10.3M in Q2 2020.
505 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.